Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
Aripiprazole/sertraline
Другие языки:

    Aripiprazole/sertraline

    Подписчиков: 0, рейтинг: 0
    Aripiprazole/sertraline
    Combination of
    Aripiprazole Atypical antipsychotic
    Sertraline Selective serotonin reuptake inhibitor
    Clinical data
    Other names ASC-01
    Routes of
    administration    		 By mouth
    Legal status
    Legal status

    Aripiprazole/sertraline (developmental code name ASC-01) is a combination formulation of aripiprazole (Abilify), an atypical antipsychotic, and sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), which was under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD). It combines serotonin reuptake inhibition from sertraline and modulation of dopamine and serotonin receptors from aripiprazole. In July 2017, it was in preregistration in Japan for the treatment of MDD. However, in September 2018, the regulatory submission in Japan for MDD was withdrawn.

    See also




    Новое сообщение